Results 251 to 260 of about 35,120,764 (296)

Correction: Targeting programmed cell death ligand 1 by CRISPR/Cas9 in osteosarcoma cells. [PDF]

Oncotarget
Liao Y, Chen L, Feng Y, Shen J, Gao Y, Cote G, Choy E, Harmon D, Mankin H, Hornicek F, Duan Z.   +10 more
europepmc   +1 more source

Prognostic value of human papilloma virus (HPV) status and programmed cell death ligand 1 (PD-L1) status in oral tongue cancer. [PDF]

Contemp Oncol (Pozn)
Szewczyk M, Ostapowicz J, Piotrowski I, Ostrowska K, Suchorska W, Golusiński W.   +5 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Programmed death ligand 1 signals in cancer cells

Nature Reviews Cancer, 2022
The paradigm of surface-expressed programmed death ligand 1 (PDL1) signalling to immune cell programmed death 1 (PD1) to inhibit antitumour immunity has helped to develop effective and revolutionary immunotherapies using antibodies blocking these cell-extrinsic interactions.
Anand V. R. Kornepati, Ratna K. Vadlamudi, Tyler J. Curiel   +2 more
openaire   +2 more sources

Resistance mechanisms to programmed cell death protein 1 and programmed death ligand 1 inhibitors

Expert Opinion on Biological Therapy, 2021
Introduction: In the past few years, administrating monoclonal humanized antibodies, namely checkpoint inhibitors, against programmed cell death protein 1 (PD-1), and its ligand (PD-L1), has yielded reassuring tumor regression rates. Anti-PD-1/PD-L1 checkpoint inhibitors disrupt the engagement of PD-1 on T-cells and their ligands on tumor or other ...
Parmida Sadat Pezeshki, Pouya Mahdavi Sharif, Nima Rezaei   +2 more
openaire   +2 more sources

Expression of programmed cell death ligand 1 and programmed cell death 1 in cutaneous warts

Journal of the American Academy of Dermatology, 2019
Cutaneous warts have high prevalence and cause significant morbidity. Understanding the mechanisms by which warts evade the immune system could lead to targeted and improved treatments.To determine whether cutaneous warts express programmed cell death ligand 1 (PD-L1) and to characterize the expression of programmed cell death 1 (PD-1) within the ...
Wesley Y, Yu, Timothy G, Berger, Jeffrey P, North, Zoltan, Laszik, Jarish N, Cohen   +4 more
openaire   +2 more sources

Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway

Journal of Medicinal Chemistry, 2018
The clinical success of inhibitors targeting the PD-1/PD-L1 pathway has made this an active field in cancer immunotherapy. Currently, most drugs targeting this pathway are monoclonal antibodies. Small-molecule inhibitors as the alternative to monoclonal antibodies are expected to overcome the disadvantages of mAbs which include production difficulties ...
Tianyu Wang, Xiaoxing Wu, Changying Guo, Kuojun Zhang, Jinyi Xu, Zheng Li, Sheng Jiang   +6 more
openaire   +2 more sources

SAR study of small molecule inhibitors of the programmed cell death‐1/programmed cell death‐ligand 1 interaction

Chemical Biology & Drug Design, 2021
AbstractThe development of small molecule inhibitors of programmed cell death‐1/programmed cell death‐ligand 1 (PD‐1/PD‐L1) has drawn research interest for the treatment of cancer. Recently, we reported the discovery of a novel dimeric core small molecule PD‐1/PD‐L1 inhibitor.
Seiji Kawashita, Koichi Aoyagi, Kyoko Fukushima, Rie Hantani, Shiori Naruoka, Atsuo Tanimoto, Yuji Hori, Yukiyo Toyonaga, Hiroshi Yamanaka, Susumu Miyazaki, Yoshiji Hantani   +10 more
openaire   +2 more sources

Progress in programmed cell death-1/programmed cell death-ligand 1 pathway inhibitors and binding mode analysis

Molecular Diversity, 2022
Programmed cell death protein 1 (PD-1)/programmed cell death protein ligand 1 (PD-L1) plays an important role in negative regulating immunity. The search for effective PD-1/PD-L1 inhibitors has been at the cutting-edge of academic and industrial medicinal chemistry, leading to the emergence of 16 clinical candidate drugs and the launch of six ...
Xiaoyun Li, Qin Zeng, Fengjiao Xu, Yuying Jiang, Zhongmei Jiang   +4 more
openaire   +2 more sources

Predictive Efficacy Biomarkers of Programmed Cell Death 1/Programmed Cell Death 1 Ligand Blockade Therapy

Recent Patents on Anti-Cancer Drug Discovery, 2016
Inhibitors of immune check-point molecule, programmed cell death 1 (PD-1) and its ligand, programmed cell death ligand 1 (PD-L1) have attracted much attention in cancer immunotherapy recently due to their durable antitumor effects in various malignances, especially the advanced ones. Unfortunately, only a fraction of patients with advanced tumors could
Xiao-Na, Fang, Li-Wu, Fu
openaire   +2 more sources